Sarepta Therapeutics
Pays vs peer median
×0.88
-12% premium
Sample
4
low confidence
Last refreshed
2026-04-13
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| rareDisease | ×0.88 | 4 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| preclinical | ×0.91 | 3 |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2025 | clinical and preclinical programs | Arrowhead Pharmaceuticals | — | unknown | $325M | $325M |
| 2025 | ARO-DM1 | Arrowhead Pharmaceuticals | DMD | unknown | $500M | $825M |
| 2025 | seven RNA programs | Arrowhead Pharmaceuticals | neurology, pulmonary, and musculoskeletal rare diseases including Huntington's and myotonic dystrophy | discovery | $500M | $10.0B |
| 2025 | TRiM platform | Arrowhead | rare muscular and CNS diseases | discovery | — | $10.0B |
| 2024 | neuromuscular | Arrowhead Pharmaceuticals | neuromuscular | preclinical | $1.1B | $1.1B |
| 2024 | seven programs | Arrowhead Pharmaceuticals | — | unknown | — | $1.0B |
| 2024 | RNA-based programs | Arrowhead Pharmaceuticals | rare diseases | phase_1 | — | $11.4B |
| 2024 | seven RNAi programs | Arrowhead | muscle diseases | unknown | $500M | $1.0B |
How this is computed
For each Sarepta Therapeutics deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 4 disclosed deal premiums vs. peer medians. Raw premium 0.879, clamped to [0.7, 1.5].